Since Jan 20, 2009
Lab Informatics (LIMS)
JOIN
45 1057
Thu March 21st, 2013
The Collaboration between MRC Technology and Chinese Academy of Sciences Targeting on Inhibiting Tum
The Collaboration between MRC Technology and Chinese Academy of Sciences Targeting on Inhibiting Tumor Angiogenesis Earlier times, researchers from the lab of the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) developed an anti-CD146 monoclonal antibody that dramatically inhibits tumor angiogenesis, migration and invasion. On Mar. 19, MRC Technology claimed that it has successfully humanized an anti-CD146 monoclonal antibody. Humanization of the antibody is an essential step in the development of anti-CD146 as a therapeutic. This project was a part of the on-going collaboration between MRC Technology and IBP CAS to develop the antibody as a cancer therapeutic. CD146, a kind of cell adhesion molecule, is important for tumor angiogenesis which might determines cancer development and metastasis. Through the collaboration, scientists hoped the positive evaluation results for the humanized antibody will prove to be a significant milestone in cancer therapy and the f
1 1 912

Want to join the conversation? Login or Register!

Search